Trends of the Use of Anti-methicillin-Resistant &lt;i&gt;Staphylococcus aureus&lt;/i&gt; Agents in Japan Based on Sales Data from 2006 to 2015

Goto, Ryota; Inose, Ryo; Kusama, Yoshiki; Kawabe, Ayako; Ishii, Saki; Ebisui, Ai; Ishikane, Masahiro; Yagi, Tetsuya; Ohmagari, Norio

doi:10.1248/bpb.b20-00605

Cited by 11 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is because all gentamicin products contain only 0.1% gentamicin. Although the AMU of oral and parenteral antibiotics have been evaluated by the amount of ingredient (1,8), it was suggested that topical AMU should be evaluated by the number of products.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017

et al. 2022

Self Cite

View full text Add to dashboard Cite

The national action plan on antimicrobial resistance (AMR) in Japan emphasizes the importance of understanding antimicrobial use (AMU). Some studies have been conducted on oral and parenteral AMU in Japan. However, there are few studies on the use of topical antimicrobials, such as in dermatology and ophthalmology. Therefore, the purpose of this study was to investigate topical AMU in Japan. Data on AMU in dermatology and ophthalmology were obtained from the 2017 National Database of Health Insurance Claims and Specific Health Checkups of Japan Open Data. The number of dermatological products used was 58,396,530 in 2017. The proportion of betamethasone/gentamicin was 50.5% and that of gentamicin 16.7%, whereas that of the ingredient quantity in gentamicin was 7.8%. It was suggested that topical AMU should be evaluated by the number of products. The number of ophthalmological products used was 24,655,653 in 2017, and the proportion of quinolones was 95.9%. The high prescription rate of quinolones may cause an increase in quinolone resistance in the ophthalmologic field. Topical AMU, which is a potential "blind spot" in the measures against AMR, needs to be continuously monitored, together with systemic AMU.

show abstract

Section: Discussionmentioning

confidence: 99%

“…AMU is often studied using the insurance claims database and sales data (7,8). The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) is an insurance claim database that contains most of the available data in the national healthcare insurance system.…”

Section: Introductionmentioning

confidence: 99%

The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…A study of anti-MRSA agent sales in Japan found that the ratio of oral linezolid to total linezolid rose from 25.5% to 39.9% between 2006 and 2015 [ 2 ]. Our study found that oral and sequential therapies might lead to more vomiting and diarrhea events than intravenous therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Linezolid is recommended as an alternative to vancomycin, a first-line drug, for treating resistant Gram-positive bacterial infections, such as MRSA osteoarthritis. With the increased use of anti-MRSA agents, the trend of vancomycin and linezolid use demonstrated a significant increase from 2006 to 2015 in Japan [ 2 ]. However, the safety and efficacy of linezolid in children remain understudied.…”

Section: Introductionmentioning

confidence: 99%

Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis

Shi

et al. 2022

World J Pediatr

View full text Add to dashboard Cite

Background We aimed to evaluate the tolerability and efficacy of linezolid in children for treating suspected and diagnosed Gram-positive bacterial infections. Methods A systematic literature search was conducted up to April 23, 2021, using linezolid and its synonyms as search terms. Two reviewers independently identified and extracted relevant randomized controlled trials and prospective cohort studies. The extracted studies were included in a single-rate meta-analysis of adverse events and clinical outcomes using random-effects models. Results A total of 1082 articles were identified, and nine studies involving 758 children were included in the meta-analysis. The overall proportion of adverse events was 8.91% [95% confidence interval (CI) = 1.64%–36.52%], with diarrhea (2.24%), vomiting (2.05%), and rash (1.72%) being the most common. The incidences of thrombocytopenia and anemia were 0.68% and 0.16%, respectively. Some specific adverse events, including rash and gastrointestinal events, were more frequent in the oral administration subgroup. In terms of efficacy, the overall proportion of clinical improvement was 88.80% (95% CI = 81.31%–93.52%). Children with a history of specific bacteriological diagnosis or concomitant antibiotic therapy had a 1.13-fold higher clinical improvement than children without such histories. The proportion of microbial eradication was 92.68% (95% CI = 84.66%–96.68%). The proportion of all-cause mortality was 0.16% (95% CI = 0.00%–7.75%). Conclusions Linezolid was well-tolerated in pediatric patients and was associated with a low frequency of adverse events, such as anemia, thrombocytopenia, and neutropenia. Moreover, linezolid was effective in children with diagnosed and suspected Gram-positive infections.

show abstract

“…It is thought that this may reflect compliance with the guidelines, the launch of new anti-MRSA drugs, and less promotion of the original agents in Japan. Goto et al [ 17 ] reported on the trends of only anti-MRSA agent use in Japan based on sales data. The total anti-MRSA agent use was found to have significantly increased from 2006 to 2015 ( p for trend = 0.027).…”

Section: Antimicrobial Stewardship With Mrsa and Extended-spectrum β-Lactamase (Esbl)-producing Enterobacteriaceaementioning

confidence: 99%

A Strategy for Hospital Pharmacists to Control Antimicrobial Resistance (AMR) in Japan

2021

View full text Add to dashboard Cite

In Japan, there is concern regarding the relation between the inappropriate use of antibiotics and antibiotic resistance (AMR). Increased bacterial resistance is due in part to the inappropriate use of antimicrobial agents. The support of the pharmacist becomes important, and there is growing interest in antimicrobial stewardship to promote the appropriate and safe use of antimicrobials needed for the optimal selection of drugs, doses, durations of therapy, therapeutic drug monitoring (TDM), and implementations of cost containment strategies in Japan. Pharmacists should strive to disseminate the concept of “choosing wisely” in relation to all medicines, implement further interventions, and put them into practice. In this article, we present data for antimicrobial stewardship and Japan’s AMR action plan, focusing on how pharmacists should be involved in enabling physicians to choose antimicrobials wisely.

show abstract

Trends of the Use of Anti-methicillin-Resistant <i>Staphylococcus aureus</i> Agents in Japan Based on Sales Data from 2006 to 2015

Cited by 11 publications

References 6 publications

The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017

The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017

Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis

A Strategy for Hospital Pharmacists to Control Antimicrobial Resistance (AMR) in Japan

Contact Info

Product

Resources

About